Skip Navigation


Annals of Oncology Advance Access originally published online on January 17, 2007
Annals of Oncology 2007 18(2):213-214; doi:10.1093/annonc/mdl483
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/2/213    most recent
mdl483v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zola, P
Right arrow Articles by Ferrero, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zola, P
Right arrow Articles by Ferrero, A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

editorials

Is carboplatin–paclitaxel combination the standard treatment of elderly ovarian cancer patients?

P Zola* and A Ferrero

Department of Gynaecologic Oncology, University of Turin, Mauriziano Hospital, Turin, Italy

* E-mail: casazola@libero.it

The first 10% of the full text of this article appears below.

Ovarian cancer is the leading cause of death from gynaecological cancer in the Western world [1]. The majority of ovarian cancer patients present with an advanced disease and show a 5-year survival rate of 25%–30%. Cytoreductive surgery combined with chemotherapy is the standard treatment of ovarian cancer. Since the 1980s clinical trials demonstrated that platinum-based chemotherapy improves survival in women with advanced disease. Carboplatin and paclitaxel association is, by now, the standard first-line chemotherapy regimen [2].

Improvement in health care and nutrition, decrease in global mortality and increasing trends of mean-life expectancy result in humans getting older compared with some decades ago. The incidence of ovarian cancer rises with advancing age, peaking in the seventh decade of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?